Cargando…

Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers

BACKGROUND: To assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease course classification may give a better estimation of the relative proportions of relapsing–remittin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forsberg, Lars, Spelman, Tim, Klyve, Pernilla, Manouchehrinia, Ali, Ramanujam, Ryan, Mouresan, Elena, Drahota, Jiri, Horakova, Dana, Joensen, Hanna, Pontieri, Luigi, Magyari, Melinda, Ellenberger, David, Stahmann, Alexander, Rodgers, Jeff, Witts, James, Middleton, Rod, Nicholas, Richard, Bezlyak, Vladimir, Adlard, Nicholas, Hach, Thomas, Lines, Carol, Vukusic, Sandra, Soilu-Hänninen, Merja, van der Walt, Anneke, Butzkueven, Helmut, Iaffaldano, Pietro, Trojano, Maria, Glaser, Anna, Hillert, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936396/ https://www.ncbi.nlm.nih.gov/pubmed/36816812 http://dx.doi.org/10.1177/20552173231153557

Ejemplares similares

The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe
por: Nicholas, Richard, et al.
Publicado: (2023)

Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network
por: Hillert, Jan, et al.
Publicado: (2021)

How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?
por: Braune, Stefan, et al.
Publicado: (2022)

Vitamin D supplementation and serum neurofilament light chain in interferon‐beta‐1b‐treated MS patients
por: Hänninen, Katariina, et al.
Publicado: (2020)

Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis
por: Sipilä, Jussi OT, et al.
Publicado: (2023)

Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study
por: Hänninen, K., et al.
Publicado: (2021)

A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment
por: Åivo, J., et al.
Publicado: (2012)

Comorbid epilepsy in Finnish patients with adult-onset Huntington’s disease
por: Sipilä, Jussi O. T., et al.
Publicado: (2016)

Parechovirus infection preceding Guillain–Barré syndrome
por: Linden, Saara, et al.
Publicado: (2012)

Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study
por: Sipilä, Jussi O. T., et al.
Publicado: (2019)

Epileptic seizures at multiple sclerosis onset and their role in disease progression
por: Grothe, Matthias, et al.
Publicado: (2023)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017)

Application of Statistical Methods for Central Statistical Monitoring and Implementations on the German Multiple Sclerosis Registry
por: Fneish, Firas, et al.
Publicado: (2023)

Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care
por: Jalusic, Kris Oliver, et al.
Publicado: (2021)

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2019)

Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2020)

The Danish Multiple Sclerosis Registry
por: Magyari, Melinda, et al.
Publicado: (2020)

Epidemiology of Guillain‐Barré syndrome in Finland 2004–2014
por: Sipilä, Jussi O.T., et al.
Publicado: (2017)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2020)

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Medication adherence/persistence among patients with active multiple sclerosis in Finland
por: Lahdenperä, Sanni, et al.
Publicado: (2020)

Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients
por: Rommer, Paulus S., et al.
Publicado: (2020)

Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate
por: Bollo, Luca, et al.
Publicado: (2022)

Relapsing and progressive MS: the sex-specific perspective
por: Rommer, Paulus Stefan, et al.
Publicado: (2020)

Comparison of employment among people with Multiple Sclerosis across Europe
por: Ellenberger, David, et al.
Publicado: (2022)

ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients
por: Lacinova, Kristyna, et al.
Publicado: (2022)

Socioeconomic status of the elderly MS population compared to the general population: a nationwide Danish matched cross-sectional study
por: Wandall-Holm, Malthe Faurschou, et al.
Publicado: (2023)

Facilitation of experimental allergic encephalomyelitis by irradiation and virus infection: role of inflammatory cells
por: Erälinna, J.P., et al.
Publicado: (1994)

Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study
por: He, Anna, et al.
Publicado: (2023)

Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study
por: Andersen, Johanna Balslev, et al.
Publicado: (2018)

A multiple sclerosis disease progression measure based on cumulative disability
por: Manouchehrinia, Ali, et al.
Publicado: (2021)

Gender differences in safety issues during Fingolimod therapy: Evidence from a real‐life Relapsing Multiple Sclerosis cohort
por: Manni, Alessia, et al.
Publicado: (2017)

Individual Differences in the Patient Experience of Relapsing Multiple Sclerosis (RMS): A Multi-Country Qualitative Exploration of Drivers of Treatment Preferences Among People Living with RMS
por: Tatlock, Sophi, et al.
Publicado: (2023)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort
por: Manni, Alessia, et al.
Publicado: (2019)

Premorbid Sociodemographic Status and Multiple Sclerosis Outcomes in a Universal Health Care Context
por: He, Anna, et al.
Publicado: (2023)

Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis
por: Manouchehrinia, Ali, et al.
Publicado: (2018)

Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis
por: He, Anna H, et al.
Publicado: (2023)

The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case–control study
por: Boles, Graysen Steele, et al.
Publicado: (2023)

Aggressive multiple sclerosis: a matter of measurement and timing
por: Ellenberger, David, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7gnc0pk12u2d3lkc5u033bc46q